Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: ...

Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15, a ...

HYDERABAD: Dr Reddy’s Laboratories SA, the wholly-owned Swiss subsidiary of Hyderabad-based pharma biggie Dr Reddy’s ...

Hyderabad: Dr Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. has announced that it has ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

Company AnnouncementNet sales of DARZALEX® in 2024 totaled USD 11,670 millionGenmab receives royalties on worldwide net sales from Johnson & ...

Ashraf Z. Badros, MB, ChB, discusses the next steps following the phase 3 AURIGA trial of daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Primary results of phase 3 AURIGA study indicated that dual maintenance therapy after transplant led to improved outcomes.

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...

Cancer therapy describes the treatment of cancer in a patient, often with surgery, chemotherapy and/or radiotherapy. Targeted therapies are also available for some cancer types. A cancer patient ...

Panelists discuss how the IMROZ trial demonstrated improved outcomes with quadruplet therapy combining daratumumab, lenalidomide, melphalan, and prednisone in patients with transplant-ineligible newly ...